BB Biotech
 | |
| Type | Aktiengesellschaft |
|---|---|
| SIX: BION, FWB: BBZA | |
| Industry | Investments |
| Founded | Schaffhausen, Switzerland (9 November 1993) |
| Headquarters | Küsnacht, Switzerland |
Key people | Erich Hunziker (Chairman) |
| Products | Investment in biotechnology companies |
 CHF 26 million (2020)[1] | |
| Total assets | CHF 3.393 billion (2019)[2] |
| Website | www.bbbiotech.ch |
BB Biotech AG is a Swiss investment company in the field of biotechnology. Since 1993 it is listed on the SIX Swiss Exchange, since 1997 on the German TecDAX and since 2000 on the Italian Borsa Italiana.[3] The company invests mainly in the US and Western Europe.[4]
History[]
Daniel Koller and Dallas J. Webb are the fund managers.[4] BB Biotech AG mainly invests in the fields of oncology, cardiovascular diseases, metabolic diseases, infectious diseases and autoimmune diseases. Its portfolio includes 20-35 companies, including Celgene, Actelion, Vertex Pharmaceuticals, Gilead Sciences, Novo Nordisk, Incyte, Isis Pharmaceuticals, ImmunoGen, Halozyme Therapeutics, Ariad Pharmaceuticals, BioMarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin Limited, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug and Idenix Pharmaceuticals.[5]
In December 2016 the company launched BB Healthcare Trust, an investment trust focused on biotech companies.[6]
As of December 31, 2019 the seven core investments in the BB Biotech portfolio were: Ionis Pharmaceuticals (13.5% of the BB Biotech Portfolio); Neurocrine Biosciences (9.5%); Incyte (8.2%); Vertex Pharmaceuticals (7.5%), Esperion Therapeutics (6.1%); Agios Pharmaceuticals (5.1%), Alnylam Pharmaceuticals (5.1%)[7]
On 30 September 2020, BB Biotech announced a net income of CHF 26 million for the period.[1]
Company Figures[]
Company figures are as follows:[8][9]
| (figures in millions CHF) | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|
| Profit/(loss) | 677.4 | (471.3) | 687.5 | (802.1) | 652.8 |
| Net Asset Value | 3393.0 | 2884.5 | 3538.7 | 3003.0 | 3978.2 |
| Market capitalization | 3670.3 | 3235.4 | 3576.1 | 3052.5 | 3463.2 |
References[]
- ^ Jump up to: a b "BB Biotech AG publishes its interim report". Dgap. 23 October 2020. Retrieved 13 April 2021.
- ^ "Annual Report 2019" (PDF). BB Biotech. Retrieved 3 June 2020.
- ^ "BB Biotech". Borsa Italiana. Retrieved 3 June 2020.
- ^ Jump up to: a b "BB Biotech AG". Bloomberg. Retrieved 15 April 2021.
- ^ "BB Biotech AG (BION) CHF1". Hargreaves Lansdown. 15 January 2021. Retrieved 19 April 2021.
- ^ "Star BB Biotech manager steps back from Healthcare trust". City Wire. 25 March 2019. Retrieved 3 June 2019.
- ^ "BB Biotech Portfolio". BB Biotech. 11 March 2020.
- ^ finanzen.net Retrieved 1st of January 2016.
- ^ "BB Biotech - Facts & Figures". BB Biotech. 11 March 2020.
External links[]
 | This Swiss corporation or company article is a stub. You can help Wikipedia by . |
- Investment companies of Switzerland
- Companies listed on the SIX Swiss Exchange
- Swiss company stubs